Imidazopyrazine inhibitors of Bruton's tyrosine kinase
US-10858364-B2 · Dec 8, 2020 · US
This page is not indexed by search engines while we improve data quality.
Acerta Pharma Bv patents in 2020
Acerta Pharma Bv was listed as an assignee on 7 patent publications in 2020.
| Metric | Value |
|---|---|
| Company | Acerta Pharma Bv |
| Year | 2020 |
| Patents | 7 |
Patents
Representative publications for Acerta Pharma Bv in 2020.
Imidazopyrazine Inhibitors of Bruton's Tyrosine Kinase
US-2020330461-A1 · Oct 22, 2020 · US
Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)-pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate
US-2020255437-A1 · Aug 13, 2020 · US
Imidazopyrazine inhibitors of Bruton's tyrosine kinase
US-10736893-B2 · Aug 11, 2020 · US
Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide for treating diffuse large B-cell lymphoma
US-10640509-B2 · May 5, 2020 · US
Top CPC classifications
Most common classification codes for Acerta Pharma Bv in 2020.
| CPC | Patents |
|---|---|
| A61K31/4985 | 7 |
| C07D487/04 | 5 |
| A61K45/06 | 4 |
| A61P29/00 | 4 |
| A61P35/00 | 4 |
Related pages
Navigate to parent entity pages.